# US 2021/0079094 A1 · Dosing of a bispecific antibody that binds pd1 and ctla4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079094 A1
- Document ID: US20210079094A1
- Status: Published application
- Kind: A1
- Application number: 16/832,440
- Filed: 2020-03-27
- Published: 2021-03-18
- Earliest claimed: 2019-03-29
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Barbara Hickingbottom; Paul Foster
- Web page: https://patentgrep.com/patent/US20210079094A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/31: multispecific
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to methods for treating a solid cancerous cancer through administering a bispecific anti-PD1 x anti-CTLA4 antibody.

## Claims

### Claim 1

A method for treating a solid cancerous tumor in a human subject, comprising:
administering to the human subject having the solid cancerous tumor an intravenous dose, once every 13-15 days, of between about 0.05 mg/kg and about 12 mg/kg of a bispecific antibody comprising a first monomer comprising SEQ ID NO: 1, a second monomer comprising SEQ ID NO: 2, and a light chain comprising SEQ ID NO: 3 for a time period sufficient to treat the solid cancerous tumor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the solid cancerous tumor is selected from the group consisting of melanoma, triple negative breast cancer, hepatocellular carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, clear cell predominant type renal cell carcinoma, high microsatellite instability colorectal carcinoma, mismatch repair deficient colorectal carcinoma, endometrial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the solid cancerous tumor is melanoma, and the melanoma is cervical carcinoma.

### Claim 4

The method of a preceding claim, wherein the intravenous dose is:
between about 0.05 mg/kg and about 0.25 mg/kg; or
between about 0.2 mg/kg and about 0.4 mg/kg; or
between about 0.5 mg/kg and about 1.5 mg/kg; or
between about 2.0 mg/kg and about 4.0 mg/kg; or
between about 8.0 mg/kg and about 12.0 mg/kg.

### Claim 5

The method of a preceding claim, wherein the intravenous dose is between about 0.15 mg/kg and about 10.0 mg/kg.

### Claim 6

The method of a preceding claim, wherein the administering of the intravenous dose to the human subject is between about 45 minutes and about 75 minutes.

### Claim 7

The method of a preceding claim, wherein the time period sufficient to treat the cancer is between about 3 weeks and about 9 weeks.

### Claim 8

The method of a preceding claim, further comprising, prior to the administering, assessing the weight of the human subject.
